University of Crete (UOC)
Ιστοειδική έκφραση ανοσορυθμιστικών μεσολαβητών σε πνευμονικό ιστό ασθενών με Χ.Α.Π. και συσχέτιση με γενετική αστάθεια στο Μικροδορυφορικό DNA
Abstract
dc:descriptionPulmonary surfactant is a complex mixture of lipids and proteins that constitutes the mobile liquid phase covering the large surface area of the alveolar epithelium. It maintains minimal surface tension within the lungs in order to avoid lung collapse during respiration. Recent studies have shown that components of Pulmonary surfactant also function in the pulmonary host defence as immune mediators. Pulmonary surfactant is composed of phospholipids, neutral lipids and surfactant proteins (SP). The SPs are divided into the hydrophobic SP-B and SP-C and the hydrophilic SP-A and SP-D. SP-B and SP-C lower the alveolar surface tension, while SP-A and SP-D are primarily concerned with host-defense functions, acting as immune mediators. Although pulmonary surfactant has the potential to contribute to the pathogenesis of COPD, very little work has been done in this field. On the other hand, in a recent study of our laboratory, detected Microsatellite DNA Instability (MSI) on G29802 (10q22) marker next to SP-A locus gene only in COPD patients. Taking into account all the evidence supporting that surfactant, especially the immunomodulatory protein SP-A, may be involved in the pathogenesis of COPD, we investigate: 1) the expression levels (by western blot and immunostaining) of SP-A in lung tissue of COPD patients in comparison to non-COPD smokers with equivalent smoking 5 history, and control non-smokers and 2) the relationship between the expression levels of SP-A and the degree of airway obstruction. To the best of our knowledge this is the first study of SP-A expression in lung tissue of COPD patients, non-COPD smokers and control non- smokers. Western blots on lung tissue specimens from 60 male subjects (32 COPD patients, 18 non-COPD smokers and 10 control non-smokers) for SP-A and the housekeeping actin, have been carried out. In addition, by immunostaining the expression pattern of the SP-A was determined in formalinfixed, paraffin-embedded lung tissue sections from the same subjects. Western blots for SP-A showed decreased, but not statistically significant, levels in COPD patients (0.6±0.7) in comparison with non-COPD smokers (2.4±0.9), (p=0.12). SP-A levels in control non-smokers were significantly higher (4.8±0.05), (p>0.05). The immunostaining showed increased overall number of pneumocytes type II cells in COPD patients but decreased ratio of SP-A positive pneumocytes type II to total pneumocyte type II cells, compared to control smokers (p=0.001). This ratio was correlated with FEV1 (%pred), (r=0.490, p=0.001). The overall number of alveolar macrophages was significantly higher in COPD patients compared to non-COPD smokers (p=0.001). The percentage of SP-A positive alveolar macrophages was higher in COPD patients versus non-COPD smokers (p=0.002) and this correlated to airway obstruction (FEV1% pred), (r=0.281, p=0.04) 6 In conclusion, our results indicate that alternate SP-A expression could be another link to COPD pathogenesis and highlights the need for further studies on surfactant markers in COPD
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vlachaki, Eleni
- Βλαχάκη, Ελένη
Subjects
dc:subject × 19- Ανοσορυθμιστικός παράγοντας
- Επιφανειοδραστικοί παράγοντες
- Πρωτεΐνη SP-A
- Μικροδορυφορικό DNA
- Πνευμονικός ιστός
- ΧΑΠ (χρόνια αποφρακτική πνευμονοπάθεια)
- Ανοσοϊστοχημεία
- Στύπωμα κατά Western
- Surfactants
- Lung tissue
- COPD
- Microsatellite DNA instability
- Immunoistochemistry
- Western blot
- Pneymocyte type II
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/24854